Reviewed for accuracy by our licensed clinical team doctors, nurse practitioners, and functional medicine specialists at The Healthy Place Clinic in Madison, WI
In phase I clinical trials, elafibranor (a dual PPAR-/PPAR- agonist) is being evaluated for its effects on liver and kidney diseases (NCT03765671, NCT03844555)
Cities Saw Record-Breaking Temperatures in 2024
It plays a central role in lipid, amino acid, glucose metabolism , and mitochondrial energy production , as well as in the synthesis of hemoglobin, neurotransmitters, cholesterol and steroid hormones , and other proteins and lipids
C th mt vi tun hoc vi thng mi thy c s thay i ca ln da nn cn kin tr s dng ng theo ch dn t c hiu qu tt nht